Genitourinary Cancers

In a recent Peer Exchange, experts discussed RCC management and treatment sequencing considerations ahead of ASCO GU 2026.

OncLive spoke with experts in the field of GU oncology to gain perspective on the biggest presentations from the 2026 Genitourinary Cancers Symposium.

The FDA has granted priority review to the sNDA seeking the approval of belzutifan plus pembrolizumab in ccRCC.

The addition of palbociclib to belzuitfan was not associated with improved responses in pretreated clear cell renal cell carcinoma.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

SBRT plus nivolumab and ipilimumab did not improve PFS vs the dual checkpoint inhibitor regimen alone in advanced RCC.

Deep and durable responses were maintained with cabozantinib plus nivolumab in long-term follow-up of the CheckMate 9ER trial.

Pembrolizumab plus belzutifan reduced the risk of having a DFS event by 28% vs pembrolizumab alone in high-risk clear cell RCC.

Belzutifan plus lenvatinib significantly prolonged PFS and showed a trend toward improved OS vs cabozantinib in advanced ccRCC after anti–PD-L1 therapy.

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

Drs Armstrong and Tawagi highlight anticipated data from the upcoming 2026 Genitourinary Cancers Symposium in prostate, bladder, and kidney cancers.

Novel pembrolizumab-based combination regimens showed similar efficacy to the reference regimen in first-line ccRCC.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

The top 5 OncLive TV videos of the week cover insights in kidney cancer, myeloproliferative neoplasms, breast cancer, systemic mastocytosis, and pancreatic cancer.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

Experts highlight key RCC studies at the 2026 Genitourinary Cancers Symposium, with a focus on combination-based strategies and patient-reported outcomes.

A meta-analysis found rapid progression and hyperprogression with nivolumab plus ipilimumab in renal medullary carcinoma.

A SEER analysis showed that immune checkpoint inhibitors better improved OS for younger patients vs older patients with advanced renal cell carcinoma.

Scott M. Haake, MD, PhD, discusses how RNAseq-defined clusters could guide treatment selection in metastatic ccRCC, based on data from the OPTIC trial.

Andrew W. Hahn, MD, discusses the efficacy and safety of lenvatinib plus everolimus in metastatic ccRCC after progression on PD-1–directed ICIs

Primo Nery “Lucky” Lara Jr, MD, has built a genitourinary oncology career inspired by optimism, rooted in perseverance, expanded by innovative thinking, and strengthened by a belief in the power of team science.

Neoadjuvant SABR before nephrectomy improved 12-month RFS vs surgery alone in patients with RCC with IVC tumor thrombus, with manageable safety.

Ciforadenant in combination with ipilimumab and nivolumab was safe and feasible but did not enhance activity in frontline ccRCC.

Pembrolizumab in the adjuvant setting yielded high DFS and OS results in addition to a manageable safety profile in real-world patients with ccRCC.